2026-01-24 09:15 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 11:13 |
[FZJ-2026-00963]
Journal Article
Konitsioti, A. M. ; Grajewski, R. ; Schlamann, M. ; et al
Successful Natalizumab Treatment of Two Female Individuals With Susac Syndrome
Background: Susac syndrome is a rare autoimmune endotheliopathy that affects the central nervous system, retina, and inner ear, characterized by encephalopathy, branch retinal artery occlusions, and sensorineural hearing loss. Due to the heterogeneity of its presentation, early diagnosis, and treatment remain challenging.Objective/methods: To evaluate the clinical outcomes and radiological responses in two patients with Susac syndrome treated with natalizumab in an off-label therapeutic approach, clinical assessments and serial magnetic resonance imaging (MRI) were performed over a follow-up period of up to 22 months to monitor disease progression and treatment response.Results: Both patients demonstrated clinical stabilization with reduced MRI and retinal angiography disease activity. [...]
OpenAccess: PDF;
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 11:08 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 10:50 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 10:29 |
[FZJ-2026-00954]
Journal Article
Konitsioti, A. M. ; Schweitzer, F. ; Johannis, W. ; et al
Serum neurofilament light chain as a biomarker of disease control in multiple sclerosis: a real-world cross-sectional analysis of therapeutic regimens
BackgroundSerum neurofilament light chain (sNfL) is an established biomarker of disease activity and progression in persons with multiple sclerosis (PwMS), with studies showing elevated sNfL levels during relapses and positive associations with disability scores.Objective To assess sNfL levels in PwMS receiving different disease-modifying therapies (DMTs), with a particular focus on extended-interval dosing (EID) regimens in real-world clinical practice.MethodsIn this two-center cross-sectional study, 172 PwMS without relapses in the preceding three months were included (University Hospital Cologne, n = 125; University Hospital Mainz, n = 47). Patients were categorized into the following groups: (1) low-efficacy DMT (leDMT; n = 8), (2) natalizumab standard-interval dosing (SID; every 4 weeks; n = 7), (3) natalizumab EID (every 6–8 weeks; n = 53), (4) ofatumumab (n = 17), (5) ocrelizumab SID (every 6 months; n = 48), (6) ocrelizumab EID (every 9 months; n = 17), and (7) no DMT (n = 19). [...]
OpenAccess: PDF;
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 10:22 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 10:13 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 09:32 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 09:03 |
Details des Eintrags - Ähnliche Datensätze
|
2026-01-23 07:44 |
Details des Eintrags - Ähnliche Datensätze
|
|
|